Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.37 |
| ▸ | NPC1 | O15118 | 5/20 | 0.37 |
| ▸ | RAB9A | P51151 | 5/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 10/20 | 0.35 |
| ▸ | HPGD | P15428 | 4/20 | 0.35 |
| ▸ | TP53 | P04637 | 3/20 | 0.34 |
| ▸ | GAA | P10253 | 3/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | F2RL3 | Q96RI0 | 4/20 | 0.33 |
| ▸ | NQO2 | P16083 | 1/20 | 0.32 |
| ▸ | FBP1 | P09467 | 1/20 | 0.32 |
| ▸ | XBP1 | P17861 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31208297 | 0.79 | KDM4E (0.51) | SMN1; SMN2KDM4ENPC1RAB9AHSD17B10 | |
| SCHEMBL1748058 | 0.79 | KDM4E (0.51) | SMN1; SMN2KDM4ENPC1RAB9AHSD17B10 | |
| SCHEMBL1748081 | 0.79 | KDM4E (0.53) | SMN1; SMN2KDM4ENPC1RAB9AHSD17B10 | |
| SCHEMBL18613864 | 0.74 | FBP1 (0.44) | SMN1; SMN2KDM4ENPC1RAB9AHSD17B10 | |
| SCHEMBL1748273 | 0.74 | FBP1 (0.44) | SMN1; SMN2ALDH1A1MAPTF2RL3FBP1 | |
| SCHEMBL31208321 | 0.74 | FBP1 (0.44) | SMN1; SMN2ALDH1A1MAPTF2RL3FBP1 | |
| SCHEMBL1748229 | 0.74 | PIK3CG (0.53) | RAB9AMAPTTP53FBP1 | |
| SCHEMBL1748264 | 0.74 | MAPT (0.41) | MAPTTP53FBP1 | |
| SCHEMBL305334 | 0.72 | LMNA (0.53) | SMN1; SMN2KDM4ENPC1RAB9AHSD17B10 | |
| SCHEMBL1748135 | 0.71 | MAPT (0.51) | SMN1; SMN2KDM4ENPC1RAB9AHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8013166-B2 | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity | BAYER HEALTHCARE LLC (US) | 2011-09-06 | — | — | US | disclosed |
| EP-1633722-B1 | PREPARATION AND USE OF ARYL ALKYL ACID DERIVATIVES FOR THE TREATMENT OF OBESITY | BAYER HEALTHCARE LLC (US) | 2011-08-03 | — | — | EP | disclosed |
| US-7968576-B2 | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity | SMITH ROGER A | 2011-06-28 | — | — | US | disclosed |
| US-20090270468-A1 | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity | SMITH ROGER | 2009-10-29 | — | — | US | disclosed |
| US-20090253762-A1 | PREPARATION AND USE OF ARYL ALKYL ACID DERIVATIVES FOR THE TREATMENT OF OBESITY | SMITH ROGER | 2009-10-08 | — | — | US | disclosed |
| US-20090197795-A1 | PREPARATION AND USE OF ARYL ALKYL ACID DERIVATIVES FOR THE TREATMENT OF OBESITY | BAYER HEALTHCARE LLC (US) | 2009-08-06 | — | — | US | disclosed |
| US-7423156-B2 | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity | BAYER PHARMACEUTICALS CORPORATION (US) | 2008-09-09 | — | — | US | disclosed |
| US-20060194859-A1 | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-08-31 | — | — | US | disclosed |
| US-7091228-B2 | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-08-15 | — | — | US | disclosed |
| CN-1816531-A | Process for the preparation of aryl alkyl acid derivatives and their use for the treatment of obesity | BAYER PHARMACEUTICALS CORP (US) | 2006-08-09 | — | — | CN | disclosed |
| US-20040224997-A1 | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity | BAYER PHARMACEUTICALS CORPORATION | 2004-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040224997-A1 | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity | FABP4, GPR119, LIPC | SMN1; SMN2 3975/4885KDM4E 817/4885NPC1 187/4885 |
| US-20060194859-A1 | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity | FABP4, GPR119, LIPC | SMN1; SMN2 3975/4885KDM4E 817/4885NPC1 187/4885 |
| US-20090270468-A1 | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity | FABP4, GPR119, LIPC | SMN1; SMN2 3975/4885KDM4E 817/4885NPC1 187/4885 |
| US-20090197795-A1 | PREPARATION AND USE OF ARYL ALKYL ACID DERIVATIVES FOR THE TREATMENT OF OBESITY | FABP4, GPR119, LIPC | SMN1; SMN2 3975/4885KDM4E 817/4885NPC1 187/4885 |
| US-20090253762-A1 | PREPARATION AND USE OF ARYL ALKYL ACID DERIVATIVES FOR THE TREATMENT OF OBESITY | FABP4, GPR119, LIPC | SMN1; SMN2 3975/4885KDM4E 817/4885NPC1 187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.